This study suggests that ovarian carcinomas demonstrate better NACT outcomes in BRCA2- vs. BRCA1-mutated hereditary ovarian carcinomas, probably due to the higher sensitivity of the former to carboplatin-paclitaxel. This evidence concerns the gene BRCA2 and ovarian carcinoma.